Baseline characteristics from the clinical trials
| Characteristic | Cryo-FIRST | STOP AF First | EARLY-AF | Pooled | ||||
| Cryo | AAD | Cryo | AAD | Cryo | AAD | Cryo | AAD | |
| Patient counts | 97 | 105 | 103 | 97 | 154 | 147 | 354 | 349 |
| Age (years) | 49.9 (12.6) | 54.4 (13.5) | 60.5 (11.2) | 61.3 (11.2) | 57.8 (11.5) | 59.7 (10.5) | 56.5 (12.4) | 58.5 (12.0) |
| Sex (% male) | 70.10% | 64.76% | 61.17% | 58.76% | 72.72% | 69.39% | 68.60% | 65.00% |
| EQ-5D-3L-derived utility | 0.89 (0.19) | 0.90 (0.15) | 0.87 (0.16) | 0.87 (0.17) | 0.88 (0.17) | 0.88 (0.16) | ||
| EHRA Class | ||||||||
| I | 0% | 0% | ||||||
| II | 69.1% | 75.2% | ||||||
| III | 28.9% | 23.8% | ||||||
| IV | 2.06% | 0.6% | ||||||
*Cells shaded grey indicate that this information was not collected in these studies.
AAD, antiarrhythmic drugs; Cryo, cryoablation; EQ-5D-3L, EuroQol 5-Dimensions 3-Levels; EHRA, European Heart Rhythm Association.